—Arrowhead Research, whose research and development operations are headquartered in Madison, said a therapeutic it’s developing could potentially prevent blood clots and treat angioedema, a condition marked by the swelling of blood vessels. Arrowhead (NASDAQ:ARWR) recently presented animal study data at the American Academy of Allergy, Asthma & Immunology Annual Meeting. The company’s stock price rose more than 10 percent, to $4.76 per share, on March 7, the day Arrowhead announced the new data, but has since fallen about 5 percent, to $4.51.
—At the same time, Arrowhead is planning to build a 45,000-square-foot laboratory in Madison, the Milwaukee Journal Sentinel reported. The new facility will be located in University Research Park on the city’s west side, and the company expects construction to be complete by August, according to the report.
—Other real estate-related news: BioForward, Wisconsin’s life sciences trade association, will open an office within the University of Wisconsin-Milwaukee’s Innovation Campus this week, BioForward CEO Lisa Johnson told Xconomy. The campus, which is located in the Milwaukee suburb of Wauwatosa and is separate from the university’s main campus, is home to organizations like TAI Diagnostics and Bridge to Cures, a nonprofit healthcare startup accelerator. BioForward had been considering opening a satellite office in the Milwaukee area since at least September 2014.
Johnson emphasized that while BioForward is based in Madison, innovative research and development is happening in many parts of the state. “We recognize that the strength of Wisconsin is in both Milwaukee and Madison, and also statewide with our manufacturing, to support a medical device industry,” she said.